NLRP3 and cardiac hypertrophy: We found that compared to 12-HETE‒treated TAC-operated WT mice, 12-HETE‒treated TAC-operated Nlrp3 KO mice had reduced cardiac cell death (Fig. 6i, j) and reduced cardiac hypertrophy (Fig. 6k).